# ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

> **NCT00394082** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ABI-007
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00394082
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-01
- **Primary completion:** 2009-09-01
- **Final completion:** 2011-02-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394082, "ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00394082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*